…, a phase III trial reported that 21% of acute migraine patients were pain-free with rimegepant (vs. placebo 11%) and 35% were free of their most bothersome symptom (vs. placebo 27%) at two hours post-dosing (Croop et al. Lancet 2019;394:737-745). Biohaven is currently enrolling patients in a phase III trial of rimegepant for migraine prophylaxis. Psychiatry Esketamine (Janssen): This N-methyl D-aspartate (NMDA) receptor blocker (Spravato) is curr…
…tion that promotes the medical and non-medical use of psychedelic drugs. For a review of MDMA in psychiatry, see Sessa et al. Front Psychiatry 2019;10:138; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC6435835/pdf/fpsyt-10-00138.pdf….
…onset and disease duration at diagnosis were not prognostic of 30-year outcomes. In contrast to other studies, baseline EDSS score was not prognostic of long-term outcomes. However, an EDSS score >2.5 at five years was prognostic of SPMS (OR 9.43). The most important metric appeared to be an early 2-point worsening of disability score in the first five years, which more strongly predicted SPMS onset (OR 40.7) than the actual EDSS score. However,…
…r an editorial see Schneider L. Lancet Neurol, epublished December 4, 2019 www.thelancet.com/action/showPdf?pii=S1474-4422%2819%2930480-6). Additional details were presented at the 12th Clinical Trials on Alzheimer’s Disease conference in San Diego in December, and reported by AlzForum (www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case). The median cumulative aducanumab exposure was 116 mg/kg…
…s discontinued, most would switch to ocrelizumab (70%). Natalizumab: Would commonly be used after fingolimod (40%). After stopping natalizumab, most would switch to ocrelizumab (63%). Ocrelizumab: Commonly used in patients previously treated with fingolimod (42%). After discontinuing, many would switch to alemtuzumab (44%). Alemtuzumab: Often preferred in patients after ocrelizumab (33%). If another therapy were needed, many would switch to ocreli…